At LIQOMICS, we strive to improve cancer treatment. Using a simple blood sample, we analyze circulating tumor DNA (ctDNA) to understand the genetic characteristics of individual tumors. With this liquid biopsy, genetic changes in a tumor can be detected and the amount of remaining tumor can be determined very precisely.
Non-invasive diagnostics through circulating tumor DNA analysis
Precise detection of minimal residual disease after therapy
Research and product development in cell-free DNA
Minimal Residual Disease (MRD), also known as measurable residual disease, refers to the small population of cancer cells that may remain in the body after treatment, such as chemotherapy, radiation therapy, or surgery. These remaining cancer cells are not detectable by conventional imaging methods such as CT or MRI, but can lead to relapse.
MRD status is an important prognostic marker in various cancer types, particularly in hematologic malignancies such as leukemias and lymphomas, but increasingly also in solid tumors. Detection of MRD is very helpful for assessing therapy response, predicting relapses, and individualizing treatment.
MRD diagnostics using liquid biopsy analyzes circulating tumor DNA (ctDNA) in blood and enables non-invasive, repeatable monitoring of disease progression. Compared to other methods, ctDNA-based MRD detection is much gentler for patients and can be performed more frequently.
Note: Detailed information on clinical studies, sensitivity/specificity and scientific evidence can be found on our page for doctors and in our publications.
Our liquid biopsy platform differs from other providers. We use duplex sequencing, gene enrichment tailored to specific tumor diseases, and proprietary bioinformatics for the highest sensitivity and specificity in genotyping and measuring minimal residual disease (MRD).
Liquid biopsy is a revolutionary, minimally invasive method for cancer diagnostics and monitoring. Unlike traditional tissue biopsies that require surgical intervention, we only need a simple blood sample - like a normal blood test at the doctor's office.
Cancer cells continuously release small DNA fragments (ctDNA) into the bloodstream. This circulating tumor DNA contains the same genetic changes as the tumor itself. By analyzing this ctDNA, we can:
For patients, this can mean: less burdensome examinations, more precise therapy decisions and better treatment outcomes.
We support patients and their doctors with diagnostic tests and the pharmaceutical industry with research services
Highly sensitive and specific ctDNA-based MRD test for solid tumors
Precise detection of minimal residual disease for various cancer types
Support for clinical trials and drug development
Do you have questions about our products and services? We are happy to advise you on your individual requirements.
The latest developments in research and product development
The GHSG HD21 substudy published in Blood demonstrates that LymphoVista detects ctDNA-MRD after just two cycles of chemotherapy, identifying patients at 5.3-fold higher risk of relapse and clarifying 70% of false-positive PET results.
The IMvigor011 trial is the first randomised Phase III study to prove that ctDNA-MRD testing can guide adjuvant immunotherapy decisions in muscle-invasive bladder cancer, with a 36% reduction in disease recurrence risk and 97.1% survival in MRD-negative patients who received no treatment.
LIQOMICS introduces liquidbiopsyinfo.com, a structured, evidence-based resource for liquid biopsy applications. Plus, our latest study on ctDNA-MRD in Hodgkin lymphoma is now published in Blood.
1 Mattlener et al. Presentation at American Society of Hematology (ASH) Annual Meeting 2024
2 Schleifenbaum et al. Presentation at European Hematology Association (EHA) Annual Meeting 2024